---
document_datetime: 2023-09-21 19:46:20
document_pages: 11
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/atryn-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
document_name: atryn-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 4.9270004
conversion_datetime: 2025-12-23 06:49:02.864916
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

| Application number   | Scope                                                                                                                                                                                                                                                         | Opinion/ Notification 1 issued on on product   | Commission Decision Issued 2 / amended Product Information affected 3   | Summary   |
|----------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------|-------------------------------------------------------------------------|-----------|
| IB/0038              | B.II.d.1.z - Change in the specification parameters and/or limits of the finished product - Other variation                                                                                                                                                   | 20/11/2018                                     | SmPC and PL                                                             |           |
| II/0033/G            | This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or | 19/07/2018                                     | Annex II                                                                |           |

<!-- image -->

30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5520 Send a question via our website www.ema.europa.eu/contact ATryn Procedural steps taken and scientific information after the authorisation 1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures. 2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). Medicinal product no longer author

<div style=\"page-break-after: always\"></div>

[-] used in the manufacture of a

<!-- image -->

manufacturer of a novel excipient A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient B.I.a.1.e - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The change relates to a biological AS or a starting material biological/immunological product B.I.a.2.c - Changes in the manufacturing process of the AS - The change refers to a [-] substance in the manufacture of a biological/immunological substance which may have a significant impact on the medicinal product and is not related to a protocol B.I.a.2.z - Changes in the manufacturing process of the AS - Other variation B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.I.d.1.b.3 - Stability of AS - Change in the storage Medicinal product no longer author

<div style=\"page-break-after: always\"></div>

| IAIN/0034         | B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing                                                                                                                                                                                                                                                                                                                     | 29/06/2018   |            | Annex II and PL     | longer                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|-------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/224/2 01707 | Periodic Safety Update EU Single assessment - antithrombin alpha                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 08/02/2018   | n/a        |                     | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| S/0030            | 10th annual re-assessment                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 14/12/2017   | n/a no     |                     | The CHMP, having reviewed the evidence of compliance with the specific obligations and the impact of the data submitted                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| T/0031            | Transfer of Marketing Authorisation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 23/10/2017   | 16/11/2017 | SmPC, Labelling and |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| II/0027           | Introduction of the first version of the RMP following request in 6th Annual Re-assessment EMEA/H/C/000587/S/0021 and second renewal EMEA/H/C/000587/R/0024. The product information has been updated accordingly to list the risk minimisation measures prior commercialisation of ATryn in each member state. In addition, the due date for the submission of the specific obligation reflected in section E of Annex II of the PI to extend the indication to the peri-partum period has been extended from 31st March 2017 to 31st March 2020. product | 23/02/2017   | 16/11/2017 | Annex II            | This variation intended to introduce the first version of the Risk Management Plan for this medicinal product. The compulsory character of RMPs as a requirement to marketing authorisation was only applicable for products submitting a marketing authorisation application after 21 July 2012. However, the marketing authorisation holder took the opportunity to introduce a risk management plan for this medicinal product. As a consequence, Annex II of the product information has been updated in accordance to the current QRD template to list risk minimisation measures in section D. In addition, the due date for the submission of the specific obligation reflected in section E of Annex II of the PI to |

<!-- image -->

Medicinal product no longer author

<div style=\"page-break-after: always\"></div>

<!-- image -->

|                   | C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH where significant assessment is required   |            | longer                                      | extend the indication to the peri-partum period has been extended from 31st March 2017 to 31st March 2020.                                                                                                                                                                                          |
|-------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|---------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/224/2 01607 | Periodic Safety Update EU Single assessment - antithrombin alpha                                                                                                                                                                                                                                 | 09/02/2017 | n/a                                         | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                   |
| S/0028            | Annual re-assessment.                                                                                                                                                                                                                                                                            | 15/12/2016 | n/a no                                      | The CHMP, having reviewed the evidence of compliance with the specific obligations and the impact of the data submitted by the MAH on the benefit/risk profile of the medicinal product, concluded that Marketing Authorisation of ATryn should be maintained.                                      |
| R/0024            | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                          | 26/05/2016 | 15/07/2016 SmPC, Annex II, Labelling and PL | Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of Atryn in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation under exceptional circumstances with unlimited validity. |
| S/0026            | The CHMP, having reviewed the evidence of compliance with the specific obligations and the impact of the data submitted by the MAH on the benefit/risk profile of the medicinal product, concluded that Marketing Authorisation of ATryn should be maintained. product                           | 26/05/2016 | n/a                                         | The CHMP, having reviewed the evidence of compliance with the specific obligations and the impact of the data submitted by the MAH on the benefit/risk profile of the medicinal product, concluded that Marketing Authorisation of ATryn should be maintained.                                      |

<div style=\"page-break-after: always\"></div>

| PSUSA/224/2 01507   | Periodic Safety Update EU Single assessment - antithrombin alpha                                                                                                                                                                                                                                                                                     | 17/03/2016   | n/a        |          | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                     |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| S/0021              | 6th Annual Re-assessment                                                                                                                                                                                                                                                                                                                             | 25/06/2015   | 08/09/2015 | Annex II | The CHMP, having reviewed the evidence of compliance with the specific obligations and the impact of the data submitted by the MAH on the benefit/risk profile of the medicinal product, concluded that Marketing Authorisation of Atryn should be varied. Specifically, the due dates for the Specific Obligations have been revised as follows: SOB 001 is now due on 31/03/ 2016 and SOB 002 is due on 31/03/2018. |
| IAIN/0023           | C.I.8.a - Introduction of or changes to a summary of Pharmacovigilance system - Changes in QPPV (including contact details) and/or changes in the PSMF location                                                                                                                                                                                      | 21/07/2015   | n/a        |          | longer                                                                                                                                                                                                                                                                                                                                                                                                                |
| PSUSA/224/2 01407   | Periodic Safety Update EU Single assessment - antithrombin alpha                                                                                                                                                                                                                                                                                     | 10/04/2015   | n/a no     |          | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                     |
| S/0020              | 5th Annual Re-assessment                                                                                                                                                                                                                                                                                                                             | 25/07/2013   | 04/10/2013 | Annex II | The CHMP, having reviewed the evidence of compliance with the specific obligations submitted by the MAH and having re-assessed the benefit/risk profile of the medicinal product, concluded that the benefit/risk balance for the product remains favourable.                                                                                                                                                         |
| IAIN/0019/G         | This was an application for a group of variations. C.I.9.a - Changes to an existing pharmacovigilance system as described in the DDPS - Change in the QPPV C.I.9.b - Changes to an existing pharmacovigilance system as described in the DDPS - Change in the contact details of the QPPV C.I.9.c - Changes to an existing pharmacovigilance product | 22/11/2012   | n/a        |          |                                                                                                                                                                                                                                                                                                                                                                                                                       |

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

B.I.a.2.b - Changes in the manufacturing process of the AS - Substantial change to the manufacturing process of the AS which may have a significant impact on the quality, safety or efficacy of the medicinal product B.I.a.4.b - Change to in-process tests or limits applied during the manufacture of the AS - Addition of a new in-process test and limits B.I.a.4.c - Change to in-process tests or limits applied during the manufacture of the AS - Deletion of a non-significant in-process test B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits B.I.b.1.f - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Change outside the approved specifications limits range for the AS B.I.c.1.c - Change in immediate packaging of the AS Liquid ASs (non sterile) B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data B.I.d.1.b.2 - Stability of AS - Change in the storage conditions - Change in storage conditions of biological/immunological ASs, when the stability studies have not been performed in accordance with a currently approved stability protocol A.4 - Administrative change - Change in the name and/or address of a manufacturer or supplier of the Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

<!-- image -->

|              |                                     |                    |               | longer                 | recommends the renewal of the Marketing Authorisation for ATryn, subject to the conditions and obligations as laid down in Annex II to the Opinion as well as the commitments of the Marketing Authorisation Holder as laid down in his Letter of Undertaking (see Attachment 4 of this Assessment Report). The Marketing Authorisation should remain under exceptional circumstances. The CHMP is however of the opinion that one additional five-year renewal on the basis of pharmacovigilance grounds is required. The MAH was requested to submit yearly PSURs unless otherwise specified by the CHMP   |
|--------------|-------------------------------------|--------------------|---------------|------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| S/0011       | Annual re-assessment.               | 18/02/2010         | 17/06/2010    |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| T/0010       | Transfer of Marketing Authorisation | 13/07/2009         | 23/07/2009    | SmPC, Labelling and PL | The Marketing Authorisation for ATryn has been transferred from LEO Pharma A/S to GTC Biotherapeutics UK Limited.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| S/0009       | Annual re-assessment.               | 22/01/2009 product | 06/03/2009 no | Annex II               | The CHMP, having reviewed the evidence of compliance with the specific obligations submitted by the MAH and having re-assessed the benefit/risk profile of the medicinal product, recommended that no amendments of Annex I and III are necessary however, an amendment of Annex II of the Commission Decision is adopted. The marketing authorisation remains under exceptional circumstances.                                                                                                                                                                                                              |
| ATryn S/0007 | Annual re-assessment. Medicinal     | 13/12/2007         | 18/02/2008    | Annex II               | The CHMP, having reviewed the evidence of compliance with the specific obligations submitted by the MAH and having re-assessed the benefit/risk profile of the medicinal product, recommended that an amendment of Annex II of the Commission Decision is necessary and that the marketing                                                                                                                                                                                                                                                                                                                   |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|         |                                                                                                                                                                                                                          |                       |                                  | authorisation remains under exceptional circumstances.                                                 |
|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------|----------------------------------|--------------------------------------------------------------------------------------------------------|
| IA/0008 | IA_28_Change in any part of primary packaging material not in contact with finished product                                                                                                                              | 23/11/2007            | n/a                              |                                                                                                        |
| IA/0006 | IA_07_a_Replacement/add. of manufacturing site: Secondary packaging site                                                                                                                                                 | 03/10/2007            | n/a                              |                                                                                                        |
| II/0002 | Update of or change(s) to the pharmaceutical documentation Change(s) to the test method(s) and/or specifications for the active substance Change(s) to the test method(s) and/or specifications for the finished product | 20/09/2007            | 25/09/2007                       | longer                                                                                                 |
| IA/0005 | IA_04_Change in name and/or address of a manuf. of the active substance (no Ph. Eur. cert. avail.)                                                                                                                       | 01/08/2007 n/a no     | Annex II                         |                                                                                                        |
| IA/0004 | IA_08_b_01_Change in BR/QC testing - repl./add. manuf. responsible for BR - not incl. BC/testing                                                                                                                         | 01/08/2007 n/a        | Annex II and PL                  |                                                                                                        |
| IB/0003 | IB_42_a_01_Change in shelf-life of finished product - as packaged for sale product                                                                                                                                       | 25/07/2007 n/a        | SmPC                             |                                                                                                        |
| T/0001  | Transfer of Marketing Authorisation                                                                                                                                                                                      | 26/11/2006 18/12/2006 | SmPC, Annex II, Labelling and PL | The Marketing Authorisation for ATryn has been transferred from Genzyme Europe B.V. to LEO Pharma A/S. |

Medicinal product no longer authorised